Iovance Biotherapeutics Q3 net loss narrows 76% year over year to $22.27 million

PUBT · 2d ago
Iovance Biotherapeutics Q3 net loss narrows 76% year over year to $22.27 million
  • Iovance Biotherapeutics’ third-quarter 2026 net loss narrowed 76% year over year to $22.27 million.
  • Revenue climbed 80% year over year to $121.47 million.
  • A supplemental approval application for lifileucel in non-squamous metastatic non-small-cell lung cancer is planned for 2027.
  • Full-year 2026 revenue guidance remains $410 million to $420 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870880) on November 05, 2026, and is solely responsible for the information contained therein.